As part of our ongoing commitment to building a greener and more responsible future, we are happy to announce the completion of the installation of 540 solar panels in one of our facilities. This action reinforces our dedication to sustainability and aligns with the Sustainable Development Goals (SDGs) outlined in the 2030 Agenda.
What does this mean for the environment?
With this installation, we are making a significant contribution to the environment by:
- Reducing our CO2 emissions by 130 tons annually, equivalent to the amount absorbed by over 6,000 trees.
- Achieving energy efficiency improvements of 18% to 30%, allowing us to use resources more responsibly.
- Generating clean, renewable energy, enough to power approximately 150 homes per year.
A commitment to positive change
This solar energy installation, with a capacity of 313.2 kWp, not only represents a significant reduction in our carbon footprint but also reaffirms our commitment to transforming our operations into a source of clean and sustainable energy. We have covered 1500 m² of our space with solar panels, marking a significant step in the fight against climate change.
Our commitment to sustainability does not stop here. We aim at driving projects for a brighter future where technology and respect for the environment go hand in hand. This is just the beginning of a series of initiatives that align our operations with sustainability and social responsibility principles.
Together, we are moving toward a greener, cleaner future for all!
Viralgen, founded in 2017 as a subsidiary of AskBio within the Bayer AG group, is a premier CDMO specializing in AAV-based gene therapies delivering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial manufacturing. Leveraging the Aava™ manufacturing platform built upon its proprietary Pro10™ suspension cell line, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes, in the world’s largest AAV-dedicated facility, to help clients scale efficiently, optimize cost of goods, and mitigate risk.
Viralgen, founded in 2017 as a subsidiary of AskBio within the Bayer AG group, is a premier CDMO specializing in AAV-based gene therapies delivering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial manufacturing. Leveraging the Aava™ manufacturing platform built upon its proprietary Pro10™ suspension cell line, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes, in the world’s largest AAV-dedicated facility, to help clients scale efficiently, optimize cost of goods, and mitigate risk.